Streptococcus In Tilapia: Vaccine Development, Field Experiences In Asia

摘要

Streptococcus species account for over half of all bacterial diseases in tilapia. The authors conducted a laboratory challenge to determine the ability of bio type-specific vaccines to protect against lethal challenge with S. agalactiae. A vaccine was effective in the lab, and in field trials, it proved safe for fish and effective against S. agalactiae biotype II. Laboratory studies have shown it protects for at least 30 weeks and can improve survival and feed conversion.